News

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival…

1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Topline results expected in fourth quarter of 2024GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:…

1 year ago

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights

- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year –…

1 year ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory…

1 year ago

Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors

Company actively advancing lead ophthalmology drug candidate to first Investigational New Drug (IND) filingREDWOOD CITY, Calif., Sept. 19, 2024 (GLOBE…

1 year ago

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a…

1 year ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded…

1 year ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Oak Ridge, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement…

1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by…

1 year ago